Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 4, 2019
- Accepted August 24, 2020
- Published online October 7, 2020.
Article Versions
- Earlier version (September 29, 2020 - 11:35).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2020 by the American Society of Nephrology
Author Information
- Adeera Levin1,
- Vlado Perkovic2,
- David C. Wheeler2,3,
- Stefan Hantel4,
- Jyothis T. George5,
- Maximilian von Eynatten5,
- Audrey Koitka-Weber5,6,7,
- Christoph Wanner7,
- on behalf of the EMPA-REG OUTCOME Investigators*
- 1Division of Nephrology, University of British Columbia, Vancouver, Canada
- 2The George Institute for Global Health, University of New South Wales, Sydney, Australia
- 3Centre for Nephrology, University College London, London, United Kingdom
- 4Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- 5Boehringer Ingelheim International GmbH, Ingelheim, Germany
- 6Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia
- 7Department of Medicine, Würzburg University Clinic, Würzburg, Germany
- Correspondence:
Dr. Adeera Levin, Division of Nephrology, St. Paul’s Hospital, University of British Columbia, 1081 Burrard Street Vancouver, BC V6Z 1Y6, Canada. Email: alevin{at}providencehealth.bc.ca
A.K.-W. and C.W. contributed equally to this work as senior authors.
Funding
Boehringer Ingelheim
Eli Lilly and Company
Statistics from Altmetric.com
Article usage
In this issue
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
Jump to section
More in this TOC Section
Original Articles
Cited By...
- No citing articles found.